Alkabbani, W., & Gamble, J. (2021). Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Des Devel Ther.
Citação norma ChicagoAlkabbani, Wajd, and John-Michael Gamble. "Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date." Drug Des Devel Ther 2021.
Citação norma MLAAlkabbani, Wajd, and John-Michael Gamble. "Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date." Drug Des Devel Ther 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.